Hindustan Unilever Limited (HUL) has filed an appeal with the Commissioner of Income Tax, challenging a tax demand of Rs 962 crore related to its acquisition of the ‘Horlicks’ brand from ...

Hindustan Unilever Ltd. has filed an appeal with the income tax appellate authority, challenging a demand of over Rs 962.75 ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

GSK GSK1.11%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...

Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Oct 10 (Reuters) - GSK (GSK.L ...

GSK’s shares rose by as much as 6.5% on Thursday before settling back slightly lower after it agreed a $2.2 billion settlement over lawsuits in the US, which alleged the drugmaker’s now ...

That news concerns a discontinued version of GSK's blockbuster heartburn drug Zantac, which was the focus of a series of lawsuits alleging that its active ingredient caused cancer. GSK announced ...

The petition was related to a demand of Rs 962.75 crores (including Rs 329.33 crores in interest) raised by the Income Tax ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

Oct 8 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in its third season after patients ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...